Zanubrutinib
Brand name: Brukinsa
Zanubrutinib comes in 4 pill versions in our database, in 2 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Zanubrutinib pill images
80 mg 2 pills
- ZANU 80 Zanubrutinib 80 mg White, capsule, 22 mm Used for mantle-cell lymphoma
- No picture yet DIN 02512963 Zanubrutinib 80 mg Brukinsa, Capsule, sold in Canada Used for mantle-cell lymphoma
160 mg 2 pills
What is Zanubrutinib used for?
Zanubrutinib is used for mantle-cell lymphoma.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Mantle Cell Lymphoma
BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Waldenström's Macroglobulinemia
BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
Marginal Zone Lymphoma
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BRUKINSA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Follicular Lymphoma
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
From the FDA-approved label on DailyMed (published Sep 14, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.